IMM–002 Systemic / IMMvention Therapeutix, Novo Nordisk - LARVOL DELTA

IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases (GlobeNewswire) - "IMMvention Therapeutix, Inc...today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will leverage IMMvention’s investigational small-molecule BACH1 inhibitors...Currently in preclinical development, IMMvention’s orally dosed BACH1 inhibitors have the potential to increase fetal hemoglobin, which is believed to ameliorate SCD disease pathology. Under the agreement, Novo Nordisk will gain an exclusive worldwide license to IMMvention’s BACH1 program. The companies will work together closely to advance BACH1 inhibitors from the program to development candidate nomination. Upon or prior to nomination of a development candidate, Novo Nordisk will take over all further development, regulatory submissions, and commercialization worldwide."

Commercial • CNS Disorders • Sickle Cell Disease